About me Social Media Strategy Magazine Writing Where It All Began Contact Page Web Editing/Development Home About Articles Contact
Diego Girón on Pexels

Ashley Barrow

“

My Articles

Xfinity •

Best Android Phones For Seniors

Finding the right smartphone can make a world of difference for seniors, providing convenience, safety, and connection to loved ones. The best phones for seniors balance user-friendly design with powerful features like long battery life and location tracking for added safety. With the right combination of features, an Android smartphone can be a powerful tool for helping seniors to stay connected, safe, and confident in the digital age. 
When choosing a senior-friendly Android phone, certain fea...
Xfinity •

The Best Android Phones For Kids & Teens: The Ultimate Guide

The best phones for kids and teens are those that strike a balance between safety and usability, offering key features like parental controls, GPS tracking, durable construction, long-lasting battery life, and a quality camera. How you prioritize which features are most important will vary by age—for younger kids, you might prioritize robust parental controls, while for teens, lighter parental controls are necessary, but battery life or operating system (OS) capabilities might be of more importa...
Xfinity •

How to Watch College Football This Season

College football season is here and fans everywhere are gearing up for months of action-packed Saturdays. Whether you’re watching from your couch or following the games on the go, there’s no shortage of ways to catch every play. From conference rivalries to nationally televised matchups, the season promises something for every fan. 
Whether by stream or broadcast TV, here are some of the ways to tune in to NCAA football this year.
With Xfinity X1, you can watch college football games in 4K for...
Xfinity •

How To Watch the NFL This Season

18 weeks. 32 teams. 272 games. And that’s not counting the playoffs. Are you ready for some football? We are. Whether you’re tuning in via your cable provider, a streaming service, or combination of the two, we’ve got the best seat in the house. Here are all the ways to watch the NFL this season.

The road to the Big Game on February 8, 2026 begins Thursday, September 4 at 8:20 PM ET on NBC and Peacock, when the title-defending Philadelphia Eagles face off with division rival Dallas Cowboys. H...
AAA Club Alliance - The Extra Mile - •

12 Super Bowl Food Ideas

Make this year’s Super Bowl menu sweet, salty, spicy, and extra savory with these game day recipes that will not leave anyone hungry at your party.

Food, family, friends, and fun define any football fanatic and we’re here to put an emphasis on food. Whether you’re planning on cozying up with a significant other to enjoy the game, tuning in with coworkers, or making it a bonding experience with friends and family, we have a recipe that will make the occasion special and festive for everyone.

There are several Super Bowl recipes to choose from, so put on your favorite football jersey and get cooking!
Prevail InfoWorks •

Awakn Initiates Investigative Study Of Novel Formulation Of (S)-Ketamine to assess dissociative effect.

The thoughtful team Awakn Life Sciences initiated an investigative study of a novel formulation of (S) – Ketamine to assess dissociative effect. Awakn is a biotechnology company focused on developing therapeutics to treat addiction. With a near-term focus on Alcohol Use Disorder (AUD), the study’s participants will consist of harmful drinkers. If the results of this study are positive, it will potentially lead to a global licensing agreement of their patent pending oral thin film (S) – Ketamine formulation.

Anthony Tennyson, Awakn CEO said, “This is an exciting development for Awakn which we believe will strengthen our innovative pipeline of therapeutics. Critically, it also has the potential to improve treatment options and experiences for so many people suffering from Alcohol Use Disorder, with so few effective options available to them, there has never been a greater need.”

#AlcoholUseDisorder #therapeutics #Phase1 #Ketamine

https://lnkd.in/eUeQagei
Prevail InfoWorks •

The rollout and readout of Alzheimer drugs is one of the biggest biotech trends that is shaping 2023.

The accelerated approval of lecanemab, branded as Leqembi, signaled a hopeful development for the treatment of Alzheimer’s disease. What else do you think is on the horizon for Alzheimer’s disease treatment?

“Beta amyloid directed antibodies have become one of the most controversial drug classes in recent history,” said Fady Riad, CEO of the consulting firm Centurion Life Sciences. “The approval of Aduhelm in 2021 led to significant scrutiny with regards to the efficacy and safety profiles of this drug and its entire class.”

#Alzheimersdisease #biotech #Alzheimers hashtag#Alzheimerstreatment

https://lnkd.in/evUdeFEs
Prevail InfoWorks •

HIV vaccine being developed by Johnson & Johnson and the U.S. National Institute of Health fails clinical trial

An experimental HIV vaccine being developed by Johnson & Johnson and the U.S. National Institute of Health wasn’t effective at preventing infection in a large study, independent trial monitors determined after reviewing initial results. The trial will be discontinued as a result. What do you think will be the next step for researchers in preventing infection?

“We are disappointed with this outcome and stand in solidarity with the people and communities vulnerable to and affected by HIV.” - Penny Heaton, M.D., Global Therapeutic Area Head for Vaccines at Janssen

#HIVvaccine #HIV #HIVprevention #clinicaltrial

https://lnkd.in/eWmhYZ2y
Prevail InfoWorks •

Sparrow Pharmaceuticals Announces First Patient Dosed in RESCUE, a Phase 2 Clinical Trial

The devoted team Sparrow Pharmaceuticals, Inc., dedicated to developing innovative therapies to address unmet needs in both endocrinology and rheumatology, are excited to share some great news. The first patient has been dosed in the phase 2 clinical trial, for the treatment of ACTC-dependent Cushing’s syndrome.

“Dosing our first patient in this phase 2 trial is an important milestone in our clinical development process of SPI-62. Cushing is a devastating rare disease with debilitating morbidities such as depression, bone loss, and diabetes, and if left untreated, high levels of mortality. Current treatments have limited efficacy or serious side effects, so there is a pressing need for new treatments that help these patients mitigate the effects of hypercortisolism.” -Frank Czerwiec, MD, PhD, Chief Medical Officer of Sparrow

#biopharma #cushingssdynrome #clinicaltrial #depression #diabetes #hypercortisolism
Prevail InfoWorks •

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

The forward-thinking team at XORTX Therapeutics Inc. Therapeutics is pleased to announce some exciting news. The late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, generated positive topline results from the XRY-OXY 101 clinical trial. Results from the study showed that XORLO was well tolerated across the various dosing regiments and no safety issues were identified in the four parts of the study.

“We are pleased to have achieved this important milestone in the development of XORLO, the Company’s proprietary oral formulation of oxypurinol. The comprehensive characterization of this drug and its unique proprietary formulation provides a substantial understanding of how the XORLO formulation behaves pharmacokinetically in individuals.” -Dr. Allen Davidoff, CEO of XORTX

#kidneydisease #biotech #newtherapies #clinicaltrial

https://lnkd.in/evMtjnqy
Prevail InfoWorks •

The diligent team at Intrommune Therapeutics is pleased to announce its completion of enrollment in the Phase 1 OMEGA Study for peanut allergy.

The results of this 48-week trial will provide long-term safety data and inform the starting dose while further defining the clinical profile of INT301. INT301 is a novel peanut desensitization immunotherapy formulated in a fully functioning toothpaste conveniently administered during a patient’s daily toothpaste routine.

https://lnkd.in/ewMaeH4A

“Fully enrolling the OMEGA Clinical Study is a significant milestone for Intrommune as we continue to progress our innovative platform of products to help patients with food allergies, including peanut allergies.” – Michael Nelson, CEO of Intrommune Therapeutics

#biotech #foodallergy #foodallergyawareness #Phase1 #peanutallergy

Prevail InfoWorks is proud to be the full service Clinical Research Organization for BriaCell Therapeutics Corp.'s upcoming pivotal study.

Expected to commence in 2023, the advanced metastatic breast cancer study will be utilizing Prevail’s clinical site coordination, project management, clinical monitoring and pharmacovigilance (safety management) services, and proprietary integrated real-time data analytics platform, The Single Interface®, for clinical support and real-time data analysis.

Please take a look at the below press release, as picked up by Bloomberg: https://lnkd.in/evYWNU6q

#Briacell #clinicaltrials #CRO #cancer #oncology #Prevail
Load More